| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $29.2M | +46.0% |
| SG&A Expense | $12.3M | +73.2% |
| Operating Income | -$41.4M | -53.2% |
| Pre-tax Income | -$39.9M | -36.7% |
| Income Tax | $0 | — |
| Net Income | -$39.9M | -36.7% |
| EPS (Basic) | -$17.98 | -10.2% |
| EPS (Diluted) | -$17.98 | -10.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $96.4M | +492.3% |
| Current Assets | $108.8M | +524.9% |
| Total Assets | $115.9M | +396.9% |
| Current Liabilities | $8.6M | +10.2% |
| Total Liabilities | $10.2M | -9.6% |
| Stockholders' Equity | -$98.8M | -63.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$32.7M | -48.5% |
| Capital Expenditures | $789K | -60.4% |
| Investing Cash Flow | -$11.8M | -153.0% |
| Financing Cash Flow | $124.6M | — |
| Free Cash Flow | -$33.5M | -39.4% |